BioFinlandin jäsen

TILT Biotherapeutics is developing a breakthrough treatment for cancer with oncolytic immunotherapy. Advanced solid tumors are currently incurable and limited treatment options are available – preclinical data on TILT technology suggests curative potential. The company was founded in 2013 and its lead product (TILT-123) is now in late preclinical stage with Phase I clinical trials starting soon. TILT’s patented technology involves utilization of oncolytic viruses for enhancement of T-cell therapy. Initial embodiments of the technology are used to enable tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T), and checkpoint inhibiting antibody (anti-PD1) therapy of solid tumors.